Insurance will play a huge role in the developing drug pricing controversy. Healthcare commentator, Ezekial Emanual, opined in yesterday’s New York Times that new drugs, particularly PCSK9 inhibitors for cholesterol control, are entering the market at prices well above their utility as measured by the extremely clinical, but widely used, “Quality-adjusted Life Years” measure. Now, of […]![]()
